tiprankstipranks
Trending News
More News >
Mineralys Therapeutics, Inc. (MLYS)
:MLYS
US Market
Advertisement

Mineralys Therapeutics, Inc. (MLYS) Ownership - Who Owns Mineralys Therapeutics, Inc.?

Compare
581 Followers

Mineralys Therapeutics, Inc. (MLYS) Ownership Overview

37.62%10.70%5.22%7.74%38.71%
37.62% Insiders
5.22% Other Institutional Investors
7.74% ETFs
38.71% Public Companies and
Individual Investors
The ownership structure of Mineralys Therapeutics, Inc. (MLYS) stock is a mix of institutional, retail, and individual investors. Approximately 23.66% of the company’s stock is owned by Institutional Investors, 37.62% is owned by Insiders, and 38.71% is owned by Public Companies and Individual Investors.
The ownership structure of Mineralys Therapeutics, Inc. (MLYS) stock is a mix of institutional, retail, and individual investors. Approximately 15.92% of the company’s stock is owned by Institutional Investors, 37.62% is owned by Insiders, and 7.74% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Nov 21, 2025
xxxxxxxxxxxxx
$43350000
Nov 13, 2025
xxxxxxxxxxxxx
$9087664
Nov 13, 2025
xxxxxxxxxxxxx
$689687
Nov 13, 2025
xxxxxxxxxxxxx
$1575976

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2025
xxxxxxxxxxxxx
$6256800
Sep 30, 2025
xxxxxxxxxxxxx
$63442169
Sep 30, 2025
xxxxxxxxxxxxx
$277716600

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
8,903,838Insider11.48%421,418,653
7,323,750Insider9.44%346,633,088
6,263,151Insider8.07%296,434,937
6,147,280Institution7.92%290,950,762
5,674,916Insider7.32%268,593,774
2,899,020Institution3.74%137,210,617
2,549,667Institution3.29%120,675,739
1,916,079Institution2.47%90,688,019
1,805,585Institution2.33%85,458,338
831,305Insider1.07%39,345,666

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
2,899,020Institution3.74%137,210,617
1,805,585Institution2.33%85,458,338
663,430Institution0.86%31,400,142
645,332Institution0.83%30,543,564
427,941Institution0.55%20,254,448
398,749Institution0.51%18,872,790
301,700Institution0.39%14,279,461
220,037Institution0.28%10,414,351
161,228Institution0.21%7,630,921
123,409Institution0.16%5,840,948

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,559,754Institution1.97%59,145,872
951,870Institution1.20%45,052,007
571,141Institution0.72%21,657,667
410,384Institution0.52%19,333,190
343,134Institution0.43%16,240,532
330,331Institution0.42%15,634,566
318,865Institution0.40%15,091,880
256,445Institution0.32%12,081,124
186,413Institution0.24%7,068,781
135,347Institution0.17%5,132,358

FAQ

Who Owns Mineralys Therapeutics, Inc. (MLYS)?
According to the latest TipRanks data, approximately 5.22% of the company's stock is held by institutional investors, 37.62% is held by insiders, and 38.71% is held by retail investors.
    What percentage of Mineralys Therapeutics, Inc. (MLYS) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 5.22% of Mineralys Therapeutics, Inc. (MLYS) stock is held by institutional investors.
      What percentage of Mineralys Therapeutics, Inc. (MLYS) stock is held by retail investors?
      According to the latest TipRanks data, approximately 38.71% of Mineralys Therapeutics, Inc. (MLYS) stock is held by retail investors.
        Who owns the most shares of Mineralys Therapeutics, Inc. (MLYS)?
        Brian Taylor Slingsby owns the most shares of Mineralys Therapeutics, Inc. (MLYS).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis